Bracco Invests in GMP Manufacturing Facility for Cell Therapy Product

Facility upgrades support clinical-grade manufacturing of Bracco's microbubble-based cell selection and activation technology

Mar. 31, 2026 at 12:23pm

Got story updates? Submit your updates here. ›

A highly textured, abstract painting in earthy tones of green, brown, and blue, featuring sweeping geometric shapes, concentric circles, and precise botanical spirals, conceptually representing the complex scientific processes and manufacturing requirements for advanced cell therapy products.Bracco's investment in a state-of-the-art GMP manufacturing facility signals the growing sophistication of the cell therapy industry and the need for specialized production capabilities.Princeton Today

Bracco Imaging, a global pharmaceutical company, has announced an investment in upgrading its manufacturing facility in Geneva, Switzerland to support clinical-grade production of its microbubble-based cell selection and activation technology. The facility is expected to be GMP (Good Manufacturing Practice) ready by mid-2027.

Why it matters

This investment by Bracco highlights the growing demand for advanced cell and gene therapy products, which require specialized manufacturing capabilities to meet rigorous quality standards. As the cell therapy industry continues to expand, having access to GMP-compliant production facilities will be crucial for companies developing these innovative treatments.

The details

The facility upgrades will enable Bracco to manufacture its microbubble-based technology, which is used for cell selection and activation in cell and gene therapy applications. This technology helps isolate and prepare specific cell types for use in therapies. By investing in this GMP-ready facility, Bracco aims to support the clinical-grade production of its cell therapy solutions.

  • Bracco announced the investment on March 31, 2026.
  • The facility is expected to be GMP ready by mid-2027.

The players

Bracco Imaging

A global pharmaceutical company that is investing in a GMP manufacturing facility for its cell therapy technology.

Got photos? Submit your photos here. ›

What’s next

Bracco expects the facility to be GMP ready by mid-2027, which will allow the company to begin clinical-grade manufacturing of its cell therapy technology.

The takeaway

Bracco's investment in a GMP-compliant manufacturing facility demonstrates the growing importance of specialized production capabilities to support the development and commercialization of advanced cell and gene therapies.